Debby Maloney
Family · Wasilla, AKNPI 1851965925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,042 and has fallen 63.0% since, to $386 in 2025. Among family clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361
- Biogen$294
- Pfizer$198
- Neurocrine Biosciences, Inc.$174
- TG Therapeutics, Inc.$169
- Eisai Inc.$142
- plus $2K from 31 others
What the payments were for
- Food & beverage$2,76397%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $361 |
| Biogen | 9 | $294 |
| Pfizer | 7 | $198 |
| Neurocrine Biosciences, Inc. | 9 | $174 |
| TG Therapeutics, Inc. | 4 | $169 |
| Eisai Inc. | 2 | $142 |
| EMD Serono, Inc. | 3 | $137 |
| AstraZeneca(2 entities) | 7 | $118 |
| Sanofi | 2 | $113 |
| Teva Pharmaceuticals USA, Inc. | 6 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $92 |
| UCB, Inc. | 4 | $86 |
| Nestle Healthcare Nutrition Inc. | 5 | $83 |
| Novo Nordisk | 4 | $81 |
| Neurelis, Inc. | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| SK Life Science, Inc. | 2 | $47 |
| Bristol Myers Squibb | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Amgen | 2 | $39 |
| Tanabe Pharma America, Inc. | 2 | $36 |
| Nevro Corp. | 1 | $33 |
| Genentech USA, Inc. | 2 | $30 |
| Radius Health, Inc. | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Novartis | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| GSK | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Viiv Healthcare Company | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,863 in reported general payments places this provider in the 90th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlatopaGlatiramer Acetate | 13 | $48,013 |
| UbrelvyUbrogepant | 16 | $17,989 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,185 |
| Lamotrigine OdtLamotrigine | 22 | $6,708 |
| Lacosamide | 34 | $5,220 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 27 | $4,023 |
| Levetiracetam | 63 | $1,182 |
| Divalproex Sodium | 21 | $1,105 |
| Clonazepam | 38 | $1,055 |
| Gabapentin | 44 | $752 |
| Carbamazepine ErCarbamazepine | 15 | $683 |
| Primidone | 25 | $613 |
| Ethosuximide | 18 | $609 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 26 | $527 |
| Memantine Hcl | 22 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $361 | $17,98916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 315 family providers in Alaska.
Other family in Wasilla
- Kymberli BrockWasilla$5K
- Sarah NielsenWasilla$4K
- Alison ArmourWasilla$4K
- Stephanie McQuillinWasilla$4K
- Liudmila FedorWasilla$4K
- Alysa SonnentagWasilla$3K
- Christine BailesWasilla$2K
- Lisa Bouyea-FranciesWasilla$2K
- Kathleen MatthewsWasilla$2K
- Erica MuchaWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.